Annual Benefit-Risk Workshop

Implementing an Internationally Acceptable Framework for the Benefit-Risk Assessment of Medicines:

How close are we to this objective?

20 - 21 June 2013

PROGRAMME

Venue: The Madison Hotel Washington, DC, USA

CENTRE FOR INNOVATION IN REGULATORY SCIENCE
The Johnson Building, 77 Hatton Garden, London EC1N 8JS, UK, Telephone: +44 (0) 207 433 4247 Email: ghepton@cirsci.org

Organiser
Professor Stuart Walker: swalker@cirsci.org
Art Gertel: agertel@cirsci.org
Neil McAuslane: nmcauslane@cirsci.org

May2013

Centre for Innovation in Regulatory Science Workshop

Background

Implementing an Internationally Acceptable Framework for the Benefit-Risk Assessment of Medicines

In 2012 at the CIRS annual workshop there was an agreement among those who are developing Benefit Risk methodologies for assessing medicines that there are four key stages namely; Framing the decision; Identifying the benefits and risks; Assessing the benefits and risks; and Interpretation and recommendation. Underpinning these was an overarching eight step framework;
1 .Decision context;
2. Building the Value Tree;
3. Value Tree refinement;
4. Assessing relative importance;
5. Evaluating options;
6. Evaluating uncertainty;
7. Concise presentation of results – visualisation;
8. Final recommendation.
All the methodologies currently being developed by regulators and pharmaceutical companies have incorporated most of these steps whether explicitly or implicitly undertaken. This overarching framework provides the basis for a common agreement on the principles for benefit risk assessment. Over the past year under the CIRS UMBRA initiative an implementation and usage guide has also been developed for the overarching framework.

There are, however, two issues remaining to be resolved within the conduct of a benefit risk assessment, one being the assessment of relative importance, and the other evaluating uncertainty. These are not explicitly included in every decision-making methodology as outlined in the overarching framework & therefore may not be considered by some as specific steps. The process of determining relative importance has been identified as particularly difficult due to perceived complexity, subjectivity and the lack of standards for the methods. Over the past year CIRS, as part of the UMBRA initiative, has been investigating the issues with companies and agencies and at this meeting proposals for consideration will be discussed and debated.

In 2012, as the development & testing of benefit-risk methodologies is taken forward by FDA, EMA, the consortium of four agencies, companies and the CIRS UMBRA initiative, this workshop will bring together the various stakeholders to answer the question – Is the overarching framework fit for purpose and are the methodologies that have been developed now being used routinely within companies and agencies and if not what are the main concerns?
.

Workshop Objectives

- **Discuss the progress** made by the different groups in 2012 in defining and implementing a benefit-risk methodology framework within their organizations.
- **Further the thinking** around assessing relative importance and uncertainty within the context making explicit benefit risk decisions and how these should be approached?
- **Develop proposals for the implementation** of the overarching framework and discuss its use from molecule to marketplace in the life cycle of medicines**.**

Venue

The Workshop will take place at The Madison Hotel in Washington DC, commencing at 09:00 on 20th June and finishing with lunch on the 21st June 2013

Style and Participation

Following the agreed practices for Institute Workshops, the meeting will be closed and attendance will be limited to allow productive networking and discussions.

Organiser
Professor Stuart Walker: swalker@cirsci.org
Art Gertel: agertel@cirsci.org
Neil McAuslane: nmcauslane@cirsci.org

Day 1: 20th June 2013

08.30 Registration

SESSION 1: IMPLEMENTING A COMMON FRAMEWORK FOR BENEFIT-RISK: HOW ARE THE DIFFERENT METHODOLOGIES PROGRESSING?		
09.00	**CIRS welcome and Framing the Workshop**	**Lawrence Liberti,** Executive Director, CIRS
09.10	**Chair's welcome and introduction**	**Dr Ed Harrigan,** Senior Vice President, Worldwide Safety and Regulatory, Pfizer, USA
	Moving from pilot programmes to routine use in development and review - If not now, when?	
09.20	**Industry viewpoint**	**Dr James Shannon,** Chief Medical Officer, GlaxoSmithKline, UK
09.45	**Regulatory Viewpoint**	**Dr Sinan Sarac,** Senior Medical Officer, Danish Health and Medicines Authority
10.10	**Discussion**	
	Benefit-Risk Framework Development: Current Status and Forward Plans *Initiatives to develop a Benefit-Risk Framework are ongoing at FDA, EMA, the consortium of four agencies and across companies. This session will provide an understanding of the main internal and external challenges, current status and forward plans.*	
10.15	**Four Agency Consortium**	**Barbara Sabourin,** Director General, Therapeutic Products Directorate, Health Canada
10.40	**Break**	
	Benefit-Risk Framework Development: Current Status and Forward Plans	
11.10	**A structured approach to benefit-risk assessment in drug regulatory decision-making: FDA viewpoint**	**Dr Patrick Frey,** Director, Office Program and Strategic Analysis, CDER, FDA, USA
11.35	**EMA Perspective**	**Dr Francesco Pignatti**, Head of Section, Oncology. Haematology & Diagnostics, European Medicines Agency
12.00	**Utilisation of UMBRA by agencies and companies**	**Dr Neil McAuslane,** Director, CIRS
12.25	**Discussion**	
12.30	**IMI PROTECT – What are the recommendations from this initiative with regard to the best way to communicate results and to whom?**	**Prof Deborah Ashby,** Professor of Medical Statistics and Clinical Trials Co-Director of Imperial Clinical Trials Unit, School of Public Health, Imperial College London, UK
12.55	**Discussion**	
13.00	**Lunch**	

Day 1: 20th June 2013

SESSION 2: BENEFIT RISK DECISION MAKING: ASSESSING RELATIVE IMPORTANCE AND UNCERTAINTY: HOW ARE THESE BEING APPROACHED AND WHAT NEEDS TO BE CONSIDERED.		
14:00	**Chairman's Introduction**	**Prof Sir Alasdair Breckenridge**
14:05	**Assessing Relative Importance – An overview of the current major approaches to weighting**	**Dr Bennett Levitan**, Director, Quantitative Safety Research, Department of Epidemiology, Janssen Research Foundation, USA
14:30	**The FDA's approach to assessing relative importance**	**Dr Robert Temple**, Deputy Center Director for Clinical Science, CDER, FDA, USA
14:55	**An industry viewpoint on weighting**	**Dr Marilyn Metcalf**, Senior Director, Benefit Risk Evaluation, GlaxoSmithKline, USA
15:20	**Discussion**	
15.30	**Break**	
16.00	**Building uncertainty into all steps of the Framework – how best to ensure all stakeholders understand the role that uncertainty has made in the expert judgement/final BR decision?**	**Dr Steven Galson,** Vice President, Global Regulatory Affairs, Amgen, USA
16.30	**Discussion**	
16.45	**Introduction to the Syndicate Sessions**	
16.50	**Syndicate sessions** *Each syndicate will undertake the following using a structured format to address the syndicate topic. Based on a proposal and a set of questions or outline, the syndicate is asked to review, debate and make recommendations to answer the question.* **A. Assessing relative importance – what guidance should be given as to how this step should be implemented by agencies and companies?** **Chair: Prof Deborah Ashby,** Professor of Medical Statistics and Clinical Trials Co-Director of Imperial Clinical Trials Unit, School of Public Health, Imperial College London, UK **Rapporteur: Dr Consuelo Blosch**, Executive Medical Director, Global Safety, Amgen Inc, USA **B. How should Patients contribute to the regulatory decision?** **Chair: Barbara Sabourin,** Director General, Therapeutic Products Directorate, Health Canada **Rapporteur: James Leong,** Senior Regulatory Specialist, Health Sciences Authority, Singapore **C. Utilisation of the Benefit Risk Framework in the post approval setting – What are the key considerations?** **Chair: Dr Ronald Robison,** Vice President, Regulatory Affairs, Patient Services and R&D QA, AbbVie Inc, USA **Rapporteur: Dr Isabelle Stoeckert,** Vice President, Head Global Regulatory Affairs Europe/Canada, Bayer Pharma AG, Germany	
18.00	**End of Session**	
19.00	**Reception**	
19.30	**Dinner**	

DAY 2: 21st June 2013

SESSION 3: SYNDICATE SESSIONS & FEEDBACK		
08.30	**Syndicate sessions resume**	
10.00	**Break**	
10.30	**Chairman's Introduction**	**Prof Sir Alasdair Breckenridge**
10.35	**Feedback of syndicate discussion and panel viewpoint following each syndicate discussion**	
11.10	**Panel Discussion** *This session is to have a reaction from different stakeholders to the ideas suggested by the syndicates as well as to facilitate discussion*.	
	Company Representative	**Dr Ed Harrigan,** Senior Vice President, Worldwide Safety and Regulatory, Pfizer, USA
	Regulatory FDA Viewpoint	**Dr Theresa Mullin,** Director, Office of Strategic Programs, CDER, FDA, USA
	Patient Viewpoint	**Dr Mary Baker,** President, European Brain Council
	New Pharmacovigilance Guidelines – One year on are companies using a structured approach to Benefit Risk and how are agencies using this internally to inform their views?	
11.55	**Regulatory Viewpoint**	**Dr Gerald Dal Pan,** Director, Office of Surveillance and Epidemiology, CDER, FDA
12.15	**Company Viewpoint**	**Dr Becky Noel,** Senior Research Scientist, Eli Lilly & Company, USA
12.35	**Discussion**	
12.45	**Making Better Use of Clinical Trials – Development of ADDIS (Aggregated Data Drug Information System) for aiding Benefit Risk Assessment of new medicines**	**Prof Hans Hillege,** Professor of Cardiology, Management Board, Department of Epidemiology, University Medical Center Groningen, The Netherlands
13:15	**The Benefit Risk Task Force what has been achieved and what action is required for the next 12 Months?**	**Prof Sir Alasdair Breckenridge**
13.25	**Summary**	
13.30	**Close of Workshop followed by lunch**	